Abstract Number: 1599 • ACR Convergence 2022
Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. The phase 3 BE COMPLETE study assessed the efficacy…Abstract Number: 2110 • ACR Convergence 2022
Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…Abstract Number: 2126 • ACR Convergence 2022
Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
Background/Purpose: Psoriatic arthritis (PsA) is a progressive condition with chronic inflammation and joint destruction impacting quality of life.1 Dactylitis and enthesitis are clinically relevant domains…Abstract Number: 2143 • ACR Convergence 2022
Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Background/Purpose: Managing pain, a predominant symptom of psoriatic arthritis (PsA), is a priority for patients and healthcare providers. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor,…Abstract Number: 0129 • ACR Convergence 2022
Effectiveness of Golimumab in the Treatment of Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Who Failed Initial TNFα Therapy: A Pooled Analysis of European Prospective Observational Studies (the GO BEYOND Program)
Background/Purpose: Patients with inflammatory arthritis often experience secondary non-response to a first-line tumor necrosis factor alpha inhibitor (TNFαi). GO-BEYOND is a study program comprised of…Abstract Number: 0395 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Background/Purpose: There is a higher prevalence of obesity in patients (pts) with psoriatic disease1. The German non-interventional study AQUILA provides real-world data on the influence…Abstract Number: 1004 • ACR Convergence 2022
SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis
Background/Purpose: Spondyloarthritis, (axial (axSpA), peripheral (pSpA)) and psoriatic arthritis (PsA)) share enthesitis as a hallmark clinical feature. Reliable clinical instruments have been developed to assess…Abstract Number: 1036 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by History of Cigarette Smoking
Background/Purpose: In patients (pts) with PsA and AS, smoking may be associated with an increased comorbidity burden, and greater responses to TNF inhibitors (TNFi) are…Abstract Number: 1209 • ACR Convergence 2022
Impact of Change in Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need for to…Abstract Number: 1493 • ACR Convergence 2022
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
Background/Purpose: There is evidence that a delay between psoriatic arthritis (PsA) symptom onset and diagnosis contributes to worse outcomes, yet the impact of delayed DMARD…Abstract Number: 1600 • ACR Convergence 2022
The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: While evidence in patients (pts) with RA suggests that switching to a therapy with a different mechanism of action (MOA) may be more effective…Abstract Number: 2111 • ACR Convergence 2022
Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA…Abstract Number: 2127 • ACR Convergence 2022
Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years
Background/Purpose: Recent guidelines from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommend that psoriatic arthritis (PsA) therapy achieve lowest possible…Abstract Number: 2144 • ACR Convergence 2022
JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis
Background/Purpose: Janus Kinase (JAK)/Signal Transducers and Activator of Transcription (STAT) is not only involved in IL23- signaling, but rather implemented into a broad range of…Abstract Number: 0189 • ACR Convergence 2022
Characteristics Associated with a Positive PEST Screening Among Patients with Psoriasis Without a Diagnosis of Psoriatic Arthritis: Results from the Global Psoriasis and Beyond Study
Background/Purpose: Psoriatic arthritis (PsA) is a common clinical feature in patients (pts) with psoriasis (PsO); up to one third of PsO pts will develop PsA…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 81
- Next Page »